Press Release

AB-Therapeutics to Present at the 5th Annual European Life Science CEO Forum for Partnering & Investing in Zurich (Switzerland), March 6-7, 2012.

March 1, 2012

AB-Therapeutics, SL announced today that Carles Domenech, PhD, Chief Executive Officer and co-Founder, will be presenting at the 5th Annual European Life Science CEO Forum for Partnering & Investing, March 6-7, 2012, at the Hilton Zurich Airport Hotel in Zurich (Switzerland). The conference gathers European investors and biopharmaceutical executives.

Dr. Domènech will present a company overview and will pursuit AB-Therapeutics’s ongoing contacts with the industry and investors.

About AB-Therapeutics
 
AB-Therapeutics is a drug research and development company founded in 2009 with headquarters in Bellaterra (Barcelona, Catalonia, Spain) at Research Park of the Autonomous University of Barcelona and a planned US development office in Boston, Massachusetts (USA) in 2013.
 
AB-Therapeutics develops highly differentiated innovative cancer drugs, with a novel mechanism of action, called Lipid Analog Therapeutics. The company has two drug candidates in development: ABTL0812, which is completing preclinical development, with planned phase Ib clinical trials in lung cancer and pancreatic cancer starting in spring 2013; and ABTL1014, expected to start preclinical development in 1Q 2013.

LATEST NEWS

05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020

Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

Press Release

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019

Press Release

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019

Press Release

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG